

# These guidelines have been withdrawn

MOH clinical practice guidelines are considered withdrawn five years after publication unless otherwise specified in individual guidelines. Users should keep in mind that evidence-based guidelines are only as current as the evidence that supports them and new evidence can supersede recommendations made in the guidelines.

# CLINICAL PRACTICE GUIDELINES

## Hormone Replacement Therapy



Ministry  
of Health



Chapter of Obstetricians & Gynaecologists  
Academy of Medicine  
Singapore

**Apr 2004**

**MOH Clinical Practice Guidelines 6/2004**

## Levels of evidence and grades of recommendation

### Levels of evidence

Level	Type of Evidence
<b>Ia</b>	Evidence obtained from meta-analysis of randomised controlled trials.
<b>Ib</b>	Evidence obtained from at least one randomised controlled trial.
<b>IIa</b>	Evidence obtained from at least one well-designed controlled study without randomisation.
<b>IIb</b>	Evidence obtained from at least one other type of well-designed quasi-experimental study.
<b>III</b>	Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies.
<b>IV</b>	Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities.

### Grades of recommendation

Grade	Recommendation
<b>A</b> (evidence levels Ia, Ib)	Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.
<b>B</b> (evidence levels IIa, IIb, III)	Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.
<b>C</b> (evidence level IV)	Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates absence of directly applicable clinical studies of good quality.
<b>GPP</b> (good practice points)	Recommended best practice based on the clinical experience of the guideline development group.

**CLINICAL PRACTICE GUIDELINES**

# **Hormone Replacement Therapy**

**MOH Clinical Practice Guidelines 6/2004**

Published by Ministry of Health, Singapore  
16 College Road,  
College of Medicine Building  
Singapore 169854

Printed by Golden City Colour Printing Co. (Pte) Ltd

Copyright © 2004 by Ministry of Health, Singapore

ISBN 981-05-1137-X

Available on the MOH website: <http://www.moh.gov.sg/cpg>

## **Statement of Intent**

These guidelines are not intended to serve as a standard of medical care. Standards of medical care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge advances and patterns of care evolve.

The contents of this publication are guidelines to clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care. Each physician is ultimately responsible for the management of his/her unique patient in the light of the clinical data presented by the patient and the diagnostic and treatment options available.

## **Foreword**

Hormone replacement therapy has the potential to be used by a great number of people. It is important that we prescribe it under the right circumstances to the right group of women who can benefit from it. As with all medication, the benefit of using the therapy must outweigh the harm.

These guidelines recommend the appropriate use of hormone replacement therapy in the treatment of menopausal symptoms and premature menopause. The guidelines also discuss the implications of the Women's Health Initiative study (WHI), a large randomised controlled trial, on the role of hormone replacement therapy in stroke, cardiovascular disease and various cancers.

I hope you find these guidelines of use to you in your practice.

DR LING SING LIN  
ACTING DIRECTOR OF MEDICAL SERVICES

# Contents

	<b>Page</b>
Executive Summary of Recommendations	1
1 Guidelines Development and Objectives	2
2 Definition of Menopause and Treatment of Menopausal Symptoms	6
3 Safety Issues of Hormone Replacement Therapy	12
4 Premature Menopause	14
5 Answers to Frequently Asked Questions on Hormone Replacement Therapy	15
6 Clinical Audit Parameters	18
References	19
Self-assessment	25
Workgroup Members	28

## Executive Summary of Recommendations

Details of recommendations can be found in the main text at the pages indicated.

**A** Hormone replacement therapy is recommended for the short-term control of vasomotor symptoms, vaginal dryness and urinary symptoms in menopause. (pg 10)

**Grade A, Level Ib**

**C** Combination hormone replacement therapy should not be used to reduce the risk of osteoporosis and subsequent fractures if it is the only indication for starting hormone replacement therapy. Alternatives such as bisphosphonates and raloxifene should instead be considered. (pg 10)

**Grade C, Level IV**

**A** Hormone replacement therapy should not be used for primary or secondary prevention of heart disease. (pg 10)

**Grade A, Level Ib**

**C** Prevention of colorectal cancer should not be the reason for long-term hormone replacement therapy. (pg 11)

**Grade C, Level IV**

**A** Hormone replacement therapy is not recommended for the prevention of Alzheimer's disease or dementia. (pg 11)

**Grade A, Level Ib**

**A** The use of unopposed hormone replacement therapy in a woman with an intact uterus has been shown to increase the risk of endometrial cancer by several fold. Therefore combined hormone replacement therapy should be used in patients with intact uteri. (pg 13)

**Grade A, Level Ia**

**C** Hormone replacement therapy is the cornerstone in the management of patients with premature menopause. It is effective in the relief of menopausal symptoms and protects against the long-term risks associated with prolonged estrogen deficiency. (pg 14)

**Grade C, Level IV**

# 1 Guidelines Development and Objectives

## 1.1 Introduction

Hormone replacement therapy (HRT) is one of the most commonly prescribed drug regimens for postmenopausal women in the world. HRT is used primarily to treat symptoms of menopause, but observational data on its beneficial effects on conditions such as osteoporosis, coronary heart disease, Alzheimer's disease and colorectal cancer has also led many women to use HRT in the hope of reducing the risks of these conditions. Recent prospective randomised controlled studies (in particular, reports arising from the Women's Health Initiative randomised controlled trial) have changed our understanding of the benefits and risks of HRT. Hence it is timely that these guidelines help to clarify the appropriate role of hormone replacement in the management of the postmenopausal woman.

## 1.2 WHI - What Is It's Implications On Postmenopausal Management?

WHI, the Women's Health Initiative study<sup>1</sup>, is a 15-year multi-million dollar health endeavour established by the US National Institutes of Health (NIH) in 1991 to address cardiovascular disease, cancer and osteoporosis in postmenopausal women. One of the major components is a randomised controlled study on HRT on the prevention of major degenerative diseases. This is the largest randomised controlled trial on one combination of hormone replacement treatment. Conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg was compared against placebo in 16,608 healthy postmenopausal women aged between 50 to 79 years (average age of 63 years) with an intact uterus from 40 North American centres over a planned 8.5 years.

This particular component of the WHI study was stopped on 31 May 2002, after a mean of 5.2 years of follow-up, by the data and safety monitoring board, due to an increased risk of invasive breast cancer. Further analysis revealed that there were increased health risks of cardiovascular disease, strokes, pulmonary embolism in addition to invasive breast cancer (7/10,000 cardiovascular disease; 8/10,000 strokes; 8/10,000 pulmonary embolism; 8/10,000 breast cancer). There were reduction of risks of endometrial cancer, hip fractures and

colorectal cancers (5/10,000 hip fractures; 6/10,000 colorectal cancers). There was no increase in deaths. However, overall health risks exceeded benefits from use of this combined estrogen-progestogen therapy. It is concluded that this regimen should not be initiated for primary prevention of coronary heart disease.

Rates of dementia including Alzheimer's disease was found to be doubled in the Women's Health Initiative Memory Study (WHIMS)<sup>2,3</sup> amongst 4,500 women 65 years and older in May 2003. The study also found that this regimen did not protect against the development of mild cognitive impairment.

The quality of life issues amongst the women in the WHI were also analysed and there were no significant effects on their general health, vitality, mental health, depressive symptoms or sexual satisfaction. At one year, there was a small but insignificant improvement in sleep disturbance, physical functioning and bodily pain but at three years there were no more significant benefits. However the WHI study did not include women in the early postmenopausal period or those who were symptomatic and their quality of life issues were not studied in the WHI.

The WHI study arm of conjugated estrogens on 11,000 hysterectomized postmenopausal women was stopped on 1 March 2004 by the National Institutes of Health (NIH) after about 7 years of follow-up. The current results showed that estrogen alone did not affect (either decrease or increase) the risk of coronary heart disease. At the same time, estrogen alone appears to marginally increase the risk of stroke and decrease the risk of hip fracture. The risk of breast cancer was not increased during the time period of this study. The results with estrogen alone replacement indicated that the increased risk of stroke is similar to that found in the trial of Estrogen plus Progestin when it was stopped after 5.2 years of follow up. With an average of nearly 7 years of follow-up completed, the study results are not likely to change if the trial continues for one more year. Thus, the NIH believes that enough data have been obtained to provide an overall assessment of the risks and benefits of the use of estrogen in this trial.

Overall the combination regime of estrogen-progestogen does not seem to be beneficial in the prevention of coronary heart disease, strokes or cognitive function especially in the older postmenopausal woman. The increase in risk of invasive breast cancer albeit small in these women over time will always limit the use of HRT in the long term, despite the positive benefits of HRT on osteoporosis and colorectal cancer. It does seem that the combined regime of HRT is probably only suitable for the early menopausal woman suffering from significant menopausal symptoms.

Although the trial was on one particular combination of hormone replacement, the findings of WHI has a potential of being extrapolated to other estrogen and progestogen preparations and has deeply affected prescriptions of hormone therapy throughout the world.

### **1.3 Objectives**

These guidelines aim to address the following issues:

- Indications for the use of hormone replacement therapy in the healthy postmenopausal woman
- Safety issues in the use of hormone replacement therapy
- Principles of treatment, dosing and optimal duration of therapy
- Treatment of premature menopause
- Answers to frequently asked questions about hormone replacement therapy

### **1.4 Guidelines Development**

These guidelines were developed by a workgroup made up of specialists in the field of obstetrics and gynaecology with a special interest in hormone replacement therapy and care of menopausal woman, as well as a family practitioner. An exhaustive search into the medical literature as well as guidelines from various colleges around the world formed the basis of these guidelines and recommendations.

## **1.5 Target Group**

Menopausal women form a large group of women patients seen by both specialists and the general practitioner. It is envisaged that these guidelines will provide a framework to update practitioners in the indications for HRT.

## **1.6 Review of Guidelines**

Evidence-based clinical practice guidelines are only as current as the evidence that supports them. Users must keep in mind that new evidence could supersede recommendations in these guidelines. The workgroup advises that these guidelines be scheduled for review three years after publication, or if new evidence appears that requires substantive changes to the recommendations.

## **2 Definition of Menopause and Treatment of Menopausal Symptoms**

### **2.1 Definition**

Menopause is defined as the end of a woman's reproductive lifespan and is achieved one year after the last period. The median age of menopause in women in Singapore is 49 years. However, the ovarian production of estrogen and progesterone begins to decline years before the complete cessation of menses and therefore menopausal symptoms start even before the cessation of menstrual periods.

Menopausal symptoms include the following:

- Vasomotor symptoms of hot flushes and night sweats
- Vaginal dryness
- Urinary frequency, urgency and stress incontinence
- Reduced libido
- Mood swings
- Insomnia

### **2.2 Dosing and Routes of Administration of Hormone Replacement Therapy**

Estrogen-only replacement therapy may be offered to women who have had hysterectomies. In women with intact uteri, estrogen should be offered with progestogen, to protect the endometrium. These may be given in a cyclical fashion, which results in regular withdrawal bleeding, or in a continuous fashion, where there is no vaginal bleeding.

Hormone replacement therapy is indicated in the patient with climacteric symptoms and the dose for the treatment should be the lowest needed for the control of symptoms and the duration of therapy should also be the shortest possible. In general 6 to 12 month period may be envisaged. However, longer periods may be necessary for more persistent symptoms. Generally menopausal symptoms will resolve within 5 years.

## Systemic Treatment:

### Estrogens

<b>Drug</b>	<b>Suggested Daily Dose</b>
<i>Oral</i>	
Conjugated Equine Estrogen (Premarin)	0.3-0.625 mg
Estradiol (Estrafem)	1-2 mg
Estradiol Valerate (Progynova)	1-2 mg
<i>Transdermal</i>	
Estradiol patch (Estraderm)	50 µg
Estrogel	1.5 mg
Estradiol Hemihydrate (Estreva gel)	1% 50 g

### Progestogens

<b>Drug</b>	<b>Suggested Daily Dose</b>
Medroxyprogesterone Acetate (Provera)	2.5, 5 or 10 mg
Dydrogesterone (Duphaston)	5, 10 or 20 mg
Norethisterone (Micronor)	2.5, 5 or 10 mg
Intrauterine L-norgestrel system (Mirena)	1 system for up to 5 years (20 ug / 24 h)
Micronised progesterone (Utrogestan)	50, 100 mg

### Cyclical Combined Therapies

<b>Oral Therapy</b>	<b>Daily Estrogen Dose</b>	<b>Progestogen Dose</b>
Estradiol valerate and norgestrel (Progyluton)	2 mg	0.5 mg for 10 days 21 day cycle
Estradiol valerate and cyproterone acetate (Climens)	2 mg	1 mg for 10 days 21 day cycle
Conjugated equine estrogen and norgestrel (Prempak-C)	0.625 mg	0.15 mg for 12 days 28 day cycle
Conjugated equine estrogen and medroxyprogesterone acetate (Premelle cycle 5)	0.625 mg	5 mg for 14 days 28 day cycle
Estradiol and dydrogesterone (Femoston)	2 mg	10 mg for 14 days 28 day cycle
Estradiol and norethisterone acetate (Trisequens)	2 mg for 22 days 1 mg for 6 days	1 mg for 10 days 28 day cycle

### Continuous Combined Therapies

<b>Combined therapy</b>	<b>Daily estrogen dose</b>	<b>Progestogen dose</b>
Conjugated equine estrogen and medroxyprogesterone acetate (Premelle 5 or Premelle 2.5)	0.625 mg	5 mg 2.5 mg
Estradiol and norethisterone acetate (Kliogest or Activelle)	2 mg 1 mg	1 mg 0.5 mg

### Local Therapy

Those with symptoms isolated to the urogenital tract should consider the use of topical estrogen therapy. With the exception of Premarin cream, there is minimal systemic absorption of the estrogen and therefore local estrogen therapy is not associated with the adverse effects seen with systemic estrogen

replacement therapy. There is also little effect on the endometrium and therefore progestogens do not have to be added. Treatment for prolonged periods may require monitoring on the effects on the endometrium.

Drug	Dosage
Estradiol pessary (Vagifem)	25 µg daily for two weeks followed by 25 µg twice a week
Conjugated equine estrogen cream (Premarin cream)*	1 g daily
Colpotrophine 1% cream	1 to 2 cm
Colpotrophine pessary 10%	1 daily up to 20 days
Estadiol ring (Estring)	2 mg estradiol vaginal ring every 90 days

\* Premarin cream – when used for vaginal atrophy should have progestogen coverage if used longer than 3 months.

Livial®<sup>4</sup> contains tibolone - a selective tissue estrogenic activity regulator (STEAR) - which regulates estrogenic activity in a tissue selective way. These tissue-selective properties of Livial enable it to provide effective relief of climacteric symptoms and vaginal atrophy, enhance mood and sexual well being and prevent osteoporosis. In the endometrium and breast tissue, it does not stimulate proliferation. The present guidelines do not include Livial as it is not an estrogen nor progestogen.

Phytoestrogens are weak estrogens found in plants and their role in the treatment of menopausal management is not substantiated with good peer-reviewed studies. They are not included in these guidelines.

### **2.3 Hormone replacement therapy is effective in the treatment of menopausal symptoms**

Hormone replacement therapy is effective in the treatment of vasomotor symptoms, vaginal dryness and the treatment of urinary symptoms, especially with surgery with some improvement in stress incontinence. Hormone replacement therapy is effective in improving the quality of life, especially in the subgroup with vasomotor symptoms.<sup>5-8</sup>

**A** Hormone replacement therapy is recommended for the short-term control of vasomotor symptoms, vaginal dryness and urinary symptoms in menopause.

**Grade A, Level Ib**

## **2.4 Role of Hormone Replacement Therapy and Osteoporosis**

Hormone replacement therapy reduces the risk for hip fractures.<sup>5</sup> However, combination HRT should not be used solely for this purpose due to its possible longer term adverse effects.

**C** Combination hormone replacement therapy should not be used to reduce the risk of osteoporosis and subsequent fractures if it is the only indication for starting hormone replacement therapy. Alternatives such as bisphosphonates<sup>9</sup> and raloxifene<sup>10</sup> should instead be considered.

**Grade C, Level IV**

## **2.5 Role of Hormone Replacement Therapy and Heart Disease**

Current evidence does not demonstrate any benefit in the use of estrogen replacement therapy<sup>11</sup> or combination hormone replacement therapy<sup>12</sup> for reduction of coronary heart disease, whether as a secondary prevention<sup>13,14</sup> measure for women at high risk of the disease, or as a primary prevention measure for women at low risk of the disease.

**A** Hormone replacement therapy should not be used for primary or secondary prevention of heart disease.

**Grade A, Level Ib**

## **2.6 Role of Hormone Replacement Therapy in the Prevention of Colorectal Cancer**

Hormone replacement therapy reduces the incidence of colorectal cancer.<sup>5</sup> However, combination HRT should not be used solely for this purpose due to its possible longer term adverse effects.

**C** Prevention of colorectal cancer should not be the reason for long-term hormone replacement therapy.

**Grade C, Level IV**

## **2.7 Role of Hormone Replacement Therapy in the Prevention of Dementia**

There is no evidence to suggest that the use of combined hormone replacement therapy improves cognition<sup>2</sup> or protects against dementia.<sup>3</sup>

**A** Hormone replacement therapy is not recommended for the prevention of Alzheimer's disease or dementia.

**Grade A, Level Ib**

### **3 Safety Issues of Hormone Replacement Therapy**

Breast tenderness, irregular vaginal bleeding and headaches are common side effects of hormone replacement. There are, in addition, other serious adverse effects.

#### **3.1 Deep Vein Thrombosis and Pulmonary Embolism**

The use of combined hormone replacement therapy is associated with a significant risk of deep vein thrombosis and pulmonary embolism.<sup>5</sup>

#### **3.2 Stroke**

The use of combined hormone replacement therapy is associated with a small increase in the incidence of ischaemic strokes<sup>1,5</sup> in healthy postmenopausal women. In contrast, combined hormone replacement therapy did not increase the risk of hemorrhagic stroke.

#### **3.3 Breast Cancer**

The long term use of combined hormone replacement therapy and estrogen replacement therapy are associated with a small but significant risk of breast cancer.<sup>5,12,15</sup> The excess risk is seen after more than 4 years of treatment.

The magnitude of this adverse effect appears to be greater among users of combined hormone replacement therapy than those on unopposed estrogen replacement therapy.<sup>5,12</sup> The excess risk is seen after more than 4 years of treatment. The estrogen-only arm of the WHI study in hysterectomized women did not show an increased incidence of breast cancer.<sup>16</sup>

There is evidence that mammographic changes associated with hormone usage may hinder and delay the diagnosis of breast cancer.<sup>15</sup>

### 3.4 Endometrial Cancer

**A** The use of unopposed hormone replacement therapy in a woman with an intact uterus has been shown to increase the risk of endometrial cancer by several fold.<sup>17,18</sup> Therefore combined hormone replacement therapy should be used in patients with intact uteri.

**Grade A, Level Ia**

Combined hormone replacement therapy, whether in cyclical regimen (with the progestin component used for > 12 days per cycle month) or in continuous regimen, has been shown to confer adequate endometrial protection and is not associated with any increased risk of endometrial cancer.<sup>19,20</sup>

## 4 Premature Menopause

### 4.1 Definition

Premature menopause is defined as spontaneous menopause before the age of 40 years.<sup>21</sup> The condition is characterized by primary or secondary amenorrhoea, infertility, sex steroid deficiency and elevated serum gonadotrophin levels. The consequence of premature ovarian failure is similar to those of the later 'natural' menopause. This condition is associated with premature loss of fecundity and the impact of health problems secondary to the long term deficiency such as osteoporosis. Premature menopause affects about 1% of women under the age of 40 years.<sup>22</sup>

### 4.2 Management of Patients with Premature Menopause

In light of more recent studies about hormone replacement therapy, it is uncertain whether the risks associated with combined HRT usage may be extrapolated to younger women with premature menopause. In these women the benefits of treatment may far outweigh the risks.

**C** Hormone replacement therapy is the cornerstone in the management of patients with premature menopause. It is effective in the relief of menopausal symptoms and protects against the long-term risks associated with prolonged estrogen deficiency.<sup>5-8</sup>

**Grade C, Level IV**

## 5 Answers to Frequently Asked Questions

**Q1: Does HRT increase the risk of cerebrovascular accidents?**

**Ans:** Estrogen plus progestin use increases the risk of ischaemic stroke in healthy postmenopausal women.<sup>1</sup>

**Q2: Does taking HRT decrease the risk of Alzheimer's disease in postmenopausal women?**

**Ans:** No. In older postmenopausal women, aged 65 years and above, estrogen plus progestin therapy did not improve cognitive function when compared to placebo. There were significantly more women in the estrogen plus progestin group with a substantial and clinically important cognitive decline.<sup>2</sup>

**Q3: Does HRT have an effect on uterine myomas in postmenopausal women?**

**Ans:** The effect of hormone replacement therapy on uterine fibroid size is controversial. Some studies have shown an increase in uterine size and myoma size, while other studies have shown no effect on uterine bleeding patterns.

Clinically, uterine myomas are generally not stimulated to grow by hormone replacement therapy. However, it is important to maintain vigilance and continue regular pelvic examinations.<sup>23-27</sup>

**Q4: What is the effect of HRT on the risk of colorectal cancer?**

**Ans:** The use of combined estrogen plus progestin therapy decreases the risk of colorectal cancer.<sup>28,29</sup> However, hormone replacement therapy is not recommended for this purpose due to its possible longer term adverse effects.

**Q5: Does HRT increase the risk of venous thromboembolism?**

**Ans:** The use of combined postmenopausal estrogen plus progestin treatment increases the risk for venous thrombosis and pulmonary embolism.<sup>28,30</sup>

**Q6: Does HRT increase the risk of carcinoma of the endometrium?**

**Ans:** No. If a woman with an intact uterus receives a preparation containing a combination of an estrogen and 12 days of progestogen, there is no increase in the risk of endometrial cancer.<sup>20,28,31-33</sup>

**Q7: Does HRT increase the risk of carcinoma of the ovary?**

**Ans:** There is no increased risk of carcinoma of the ovary in users of postmenopausal estrogen plus progestin replacement therapy.

There may be an increased risk of ovarian cancer in women who use unopposed estrogen for a long time and the magnitude of risk noted is low.<sup>28,34,35</sup>

**Q8: Can HRT increase the risk of recurrence of endometriosis after surgery?**

**Ans:** The common denominator for endometriosis formation appears to be exposure to female hormones.

In girls with gonadal dysgenesis, there have been case reports describing endometriosis development after initiation of estrogen therapy.

There are even case reports of men developing endometriosis after receiving high doses of estrogen therapy for bladder or prostate cancer.

It has been shown that a minority of women develop a recurrence of endometriosis after radical surgery related to the commencement of hormone replacement therapy.

There are also case reports of endometriosis arising de novo following hormone replacement therapy.

Case reports have suggested that the use of unopposed estrogen may lead to premalignant or malignant transformation in residual foci of endometriosis.<sup>36-47</sup>

**Q9: Does HRT usage worsen the blood pressure in hypertensive women?**

**Ans:** No. Estrogens at the doses used for postmenopausal HRT have been found to either have no effect on blood pressure or to cause a small but statistically significant decrease.<sup>48-51</sup>

## 6 Clinical Audit Parameters

The following clinical audit parameter is proposed:

- Percentage of women with intact uteri on hormone replacement therapy receiving estrogen-only therapy.

The use of unopposed hormone replacement therapy in a woman with an intact uterus has been shown to increase the risk of endometrial cancer by several fold.<sup>17,18</sup> Therefore combined hormone replacement therapy should be used in patients with intact uteri.

## References

1. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A et al. WHI investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized controlled trial. *JAMA* 2003; 289: 2673-84.
2. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE et al; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women; the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA* 2003; 289: 2663-72.
3. Shumaker SA, Legault C, Thal L, Wallace RB, Ockene JK, Hendrix SL, et al. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA* 2003; 289: 256-62.
4. Palacios S Tibolone: what does tissue specific activity mean? *Maturitas*. 2001 Jan 31;37(3):159-65. Review.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al: Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principle results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002; 288: 321-33.
6. Davis SR. Premature ovarian failure. *Maturitas* 1996; 23: 1-8.
7. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. *Pharmacotherapy* 2001; 21:464-80.
8. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. *Obstet Gynecol* 1998; 92:722-7,
9. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomized trial of effect of alendronate on risk of fracture

- in women with existing vertebral fractures. Fractures Intervention Trial Research Group. *Lancet* 1996; 348: 1535-41.
10. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *JAMA* 1999; 282: 637-45.
  11. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Synder TE et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. *N Engl J Med* 2000; 343: 522-9
  12. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med* 2003; 349: 523-34.
  13. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA* 1998; 280: 605-13.
  14. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up HERS II. *JAMA* 2002; 288: 49-57.
  15. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. *Lancet* 2003; 362: 419-27.
  16. *The Lancet*. Vol 363. Mar 13, 2004. [www.the.lancet.com](http://www.the.lancet.com).
  17. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. *JAMA* 2003; 289: 3243-53.

18. Shields TS, Weiss NS, Voight LF, Beresford SA. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. *Epidemiology* 1999; 10: 733-8.
19. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lingren A et al. Risk of endometrial cancer following estrogen replacement with and without progestins. *J Natl Cancer Inst* 1999; 91: 1131-7.
20. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol* 1995; 85: 304-13.
21. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC et al. Estrogen-progestin replacement therapy and endometrial cancer. *J Natl Cancer Inst* 1997; 89: 1110-6.
22. Laml T, Schulz-Lobmeyr I, Obtruca A, Huber JC, Hartmann BW. Premature ovarian failure: etiology and prospects. *Gynecol Endocrinol* 2000; 14: 292-302.
23. Yang CH, Lee JN, Hsu SC, Kuo CH, Tsai EM. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women - a 3-year study. *Maturitas* 2002; 43: 35.
24. Sener AB, Seckin NC, Ozmen S et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. *Fertil Steril* 1996; 65: 354-7.
25. Colacurci N, deFranciscis P, Cobellis L, Nazzaro G, dePlacido G. Effects of hormone replacement therapy on postmenopausal uterine myoma. *Maturitas* 2000; 35:167-73.
26. Palomba S, Sena T, Noia R, Di Carlo C, Zullo F, Mastrantonio P. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. *Obstet Gynecol* 2001; 98: 1053-8.
27. Speroff L, Glass RH, Kase NG. *Clinical gynecologic endocrinology and infertility*. 6<sup>th</sup> edition. Baltimore MD: Williams and Wilkins, 726-79.

28. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002; 288: 321-33.
29. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, laVecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. *Int J Cancer* 2003; 105: 408-12.
30. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998; 280: 605-18.
31. Sturdee DW, Wade ET, Paterson MEL et al. Relations between bleeding patterns, endometrial histology and estrogen treatment in menopausal women. *Br Med J* 1978; 8127: 1575-7.
32. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. *JAMA* 1996; 275: 370-5.
33. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - longterm follow-up of a Swedish cohort. *Int J Cancer* 1996; 67: 327-32.
34. Sia AS, Modugno F, Weissfeld JL, Berga SL, Ness RB. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. *Gynecol Oncol* 2002; 86: 118-23.
35. Lacey JV, Mink PJ, Lubin JH et al. Menopausal hormone replacement therapy and risk of ovarian cancer. *JAMA* 2002; 288: 334-41.
36. Doty DW, Gruber JS, Wolf GC, Winslow RC. 46XY pure gonadal dysgenesis: report of 2 unusual cases. *Obstet Gynecol* 1980; 55: 61S-65S.

37. Peress MR, Sosnowski JR, Mathur RS and Williamson SO. Pelvic endometriosis and Turner's syndrome. *Am J Obstet Gynecol* 1982; 144: 474-6.
38. Binns BAO and Banerjee R. Endometriosis with Turner's syndrome treated with cyclical estrogen/progestogen. *Br J Obstet Gynecol* 1983; 90: 581-2.
39. Bosze P, Gaal M, Toth A, Laszlo J. Endometriosis and streak gonad syndrome. *Arch Gynecol* 1987; 240: 253-4.
40. Tazuke SI, Milki AA. Endometrioma of uterine serosa in a woman with mosaic Turner's syndrome receiving hormone replacement therapy: case report. *Hum Reprod* 2002; 17: 2977-80.
41. Olikier AJ, Harris AE. Endometriosis of the bladder in a male patient. *J Urol* 1971; 106: 858-9.
42. Pinkert TC, Catlow CE, Strays R. Endometriosis of urinary bladder in a man with prostate carcinoma. *Cancer* 1979; 43: 1562-7.
43. Brough RJ, O'Flynn K. Recurrent pelvic endometriosis and bilateral ureteric obstruction associated with hormone replacement therapy. *Br Med J* 1996; 312: 1221-2.
44. Goh JT, Hall BA. Postmenopausal endometrioma and hormone replacement therapy. *Aust NZ J Obstet Gynecol* 1992; 32: 384-5.
45. Matorras R, Elorriaga MA, Pijoan JI, Ramon O, Rodriguez-Escudero FJ. Recurrence of endometriosis in women with bilateral adnexectomy (with or without hysterectomy) who received hormone replacement therapy. *Fertil Steril* 2002; 77: 303-8.
46. Chingwundoh FI, Ryan P, Lusley T, Chan SY. Renal and diaphragmatic endometriosis de novo associated with hormone replacement therapy. *J Urol* 1995; 153: 380-1.
47. Gucer F, Pieber D, Arikan MG. Malignancy arising in extra-ovarian endometriosis during estrogen stimulation. *Eur J Gynaecol Oncol* 1998; 19: 39-41.

48. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, Rajzer M, Jankowski P. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. *J Hum Hypertens* 2002; 16: 509-16.
49. Wren BG, Routledge AD. The effect of type and dose of estrogen on the blood pressure of postmenopausal women. *Maturitas* 1983; 5: 135-42.
50. Hassager C, Christiansen C. Blood pressure during estrogen/progestin substitution therapy in healthy postmenopausal women. *Maturitas* 1988; 9:315-23.
51. Lim GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. *J Hum Hypertens* 1994; 8: 491-4.



6. A history of breast cancer is a definite contraindication to the usage of hormone replacement therapy.

A. True                      B. False

7. Oral estrogen replacement therapy is more effective than topical vaginal estrogens in the treatment of urogenital symptoms associated with menopause.

A. True                      B. False

8. Estrogen replacement alone when used in a post-hysterectomy patient is not associated with an increased risk of breast cancer.

A. True                      B. False

## **Answers:**

1. False
2. False
3. False
4. False
5. True
6. True
7. False
8. True

## Workgroup members

The members of the workgroup, who were appointed in their personal professional capacity, are:

**Chairman**                      **Dr Yu Su Ling**  
**Head & Senior Consultant**  
**Dept of Obstetrics and Gynaecology**  
**Singapore General Hospital**

### Members

**Dr Lee Puay Hoon, Julinda**  
**Associate Consultant**  
**Dept of Obstetrics and**  
**Gynaecology**  
**Singapore General Hospital**

**Dr Yeoh Swee Choo**  
**The Obstetrics & Gynaecology**  
**Practice**  
**Mount Elizabeth Medical**  
**Centre**

**Dr Lisa Chin Yue Kim**  
**Chin Y K Clinic for Women and**  
**Menopause Centre**  
**Gleneagles Medical Centre**

**Dr Khong Chit Chong**  
**Head and Senior Consultant**  
**Menopause Unit**  
**KK Women & Children's**  
**Hospital**

**Dr Phyllis Liauw**  
**TLC Gynaecology Practice**  
**Thomson Medical Centre**

**Dr Oei Pau Ling**  
**My Gynae Women's Clinic**  
**Gleneagles Medical Centre**

**Dr Sandy Lek**  
**Joo Chiat Clinic for Women**

**Dr Loh Foo Hoe**  
**Women's Specialist Associates**  
**Mount Elizabeth Medical**  
**Centre**

**Dr Ling Yee Kiang**  
**Geylang Polyclinic**

# MOH CLINICAL PRACTICE GUIDELINES 6/2004

## Hormone Replacement Therapy



Ministry  
of Health



Chapter of Obstetricians & Gynaecologists  
Academy of Medicine  
Singapore

### Executive summary of recommendations

Details of recommendations can be found in the main text at the pages indicated.

**A** Hormone replacement therapy is recommended for the short-term control of vasomotor symptoms, vaginal dryness and urinary symptoms in menopause. (pg 10)

**Grade A, Level Ib**

**C** Combination hormone replacement therapy should not be used to reduce the risk of osteoporosis and subsequent fractures if it is the only indication for starting hormone replacement therapy. Alternatives such as bisphosphonates and raloxifene should instead be considered. (pg 10)

**Grade C, Level IV**

**A** Hormone replacement therapy should not be used for primary or secondary prevention of heart disease. (pg 10)

**Grade A, Level Ib**

**C** Prevention of colorectal cancer should not be the reason for long-term hormone replacement therapy. (pg 11)

**Grade C, Level IV**

**A** Hormone replacement therapy is not recommended for the prevention of Alzheimer's disease or dementia. (pg 11)

**Grade A, Level Ib**

**A** The use of unopposed hormone replacement therapy in a woman with an intact uterus has been shown to increase the risk of endometrial cancer by several fold. Therefore combined hormone replacement therapy should be used in patients with intact uteri. (pg 13)

**Grade A, Level Ia**

**C** Hormone replacement therapy is the cornerstone in the management of patients with premature menopause. It is effective in the relief of menopausal symptoms and protects against the long-term risks associated with prolonged estrogen deficiency. (pg 14)

**Grade C, Level IV**